Welcome to our dedicated page for Bristol-Myers Squibb news (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb stock.
Bristol Myers Squibb reports news on its pharmaceutical portfolio across oncology, cardiovascular disease and immunology, including regulatory decisions, clinical trial data, commercial access programs and product collaborations. Company updates include Sotyktu (deucravacitinib), a selective TYK2 inhibitor approved in the European Union for active psoriatic arthritis, and Eliquis (apixaban), an oral anticoagulant marketed through the Bristol Myers Squibb-Pfizer alliance.
Recurring developments also cover quarterly financial results, investor conference participation, debt and capital-market activity, research collaborations in cardiovascular and precision-medicine programs, and community initiatives tied to multiple myeloma care. The company’s news flow combines product-specific regulatory milestones with broader disclosures on operating performance and pipeline partnerships.
SystImmune and Bristol Myers Squibb (NYSE: BMY) presented first global Phase I results for iza-bren (EGFR x HER3 bispecific ADC) at ESMO 2025 on Oct 17, 2025.
At data cut-off July 23, 2025, 107 heavily pre-treated patients were treated. At 2.5 mg/kg (Days 1 & 8 q3w), confirmed response rate was 55% (11/20) with median progression-free survival 5.4 months. Confirmed responses occurred in EGFR-mutated (3/10) and EGFR wild-type (3/4) NSCLC subgroups. No interstitial lung disease observed; hematologic AEs (neutropenia) were manageable and prompted mandatory preventative measures in ongoing studies. Breakthrough Therapy designation granted Aug 2025.
insitro and Bristol Myers Squibb (NYSE: BMY) extended their collaboration on October 14, 2025 to apply insitro’s ChemML™ platform toward discovery of small-molecule therapies for a novel preclinical ALS target identified in the prior biological evaluation phase.
The one-year extension may provide up to $20 million in new funding and the partnership could deliver a program with aggregate milestone and royalty value exceeding $2 billion. ChemML™ capabilities cited include large-scale QAL data generation, ADMET modeling, an AI-driven design loop, and a 192 H100 GPU compute cluster.
Bristol Myers Squibb (NYSE: BMY) will present oncology data at ESMO Congress 2025 in Berlin, Oct 17–21, showcasing results from >50 company‑sponsored, investigator‑sponsored and collaborative studies across >10 cancer types.
Key highlights include first disclosure of a global Phase 1 study of iza‑bren (BL‑B01D1) (EGFR×HER3 ADC) and data that supported an FDA Breakthrough Therapy designation; late‑breaking PFS and first OS from CheckMate‑8HW in MSI‑H/dMMR mCRC; five‑year DFS/OS/ctDNA follow‑up from CheckMate‑274 in high‑risk MIUC; and the nine‑year final analysis of CheckMate‑238 in resected advanced melanoma.
SystImmune (collaborating with BMY) announced the first patient treated in the IZABRIGHT-Breast01 Phase 2/3 registrational study of izalontamab brengitecan (iza-bren) in previously untreated triple negative breast cancer ineligible for anti-PD(L)1 drugs.
That event triggered a $250 million one-time milestone payment from Bristol Myers Squibb (BMY) under the 2023 collaboration and exclusive license agreement. SystImmune is eligible for up to an additional $250 million near-term and up to $7.1 billion in further contingent development, regulatory and sales milestones. Iza-bren has received Breakthrough Therapy Designation from the FDA for previously treated advanced EGFR-mutated NSCLC and is being evaluated in multiple ongoing global trials.
Bristol Myers Squibb (NYSE: BMY) will acquire Orbital Therapeutics for $1.5 billion cash at closing, adding Orbital’s lead preclinical program OTX-201 and a proprietary RNA platform that combines circular and linear RNA, targeted LNP delivery, and AI-driven design.
The deal aims to expand BMS’s cell therapy portfolio by enabling in vivo CAR T approaches intended to reduce treatment burden and broaden patient access for autoimmune diseases. Closing is subject to customary conditions, including the Hart-Scott-Rodino waiting period, and accounting treatment will be determined at close.
Bristol Myers Squibb (NYSE: BMY) launched COBENFY Connections on October 10, 2025 to reduce stigma around schizophrenia by sharing real stories from adults taking COBENFY™ (xanomeline and trospium chloride), their care partners, and clinicians.
The program, introduced on World Mental Health Day, features TV host Gail Simmons discussing her brother’s lived experience and a hosted gathering that highlighted peer support, treatment exploration, and community connection. The initiative directs audiences to connections.bms.com and includes Important Safety Information for COBENFY.
Bristol Myers Squibb (NYSE: BMY) announced that its anti-MTBR-tau antibody, BMS-986446, has received Fast Track Designation from the FDA for early Alzheimer's disease treatment. The drug, currently in Phase 2 development, targets pathological tau protein fragments and aims to modify the disease's progression by neutralizing tau spread and promoting its clearance.
The investigational therapy has shown promising results in preclinical models, demonstrating significant reductions in tau uptake and spread, and protection against behavioral deficits. A Phase 1 study confirmed safety and tolerability across three dose cohorts. The ongoing Phase 2 study is fully enrolled and will evaluate the drug's impact on disease progression through various biomarkers and clinical outcome measures.
Bristol Myers Squibb (NYSE: BMY) has expanded its direct-to-patient program by introducing the new BMS Patient Connect platform, offering significant discounts on two key medications. Eliquis (apixaban) will be available at over 40% below list price, while Sotyktu (deucravacitinib) will be offered at more than 80% discount starting January 2026.
The initiative aims to improve medication accessibility and affordability across all 50 states and Puerto Rico for eligible cash-paying patients. Sotyktu, a first-in-class TYK2 inhibitor, is used to treat moderate-to-severe plaque psoriasis in adults. The platform will provide patient support resources and may include additional BMS medicines in the future.
Bristol Myers Squibb (NYSE:BMY) announced positive interim results from its Phase 3 EXCALIBER-RRMM study of iberdomide, a novel CELMoD™ therapy, in combination with daratumumab and dexamethasone for relapsed or refractory multiple myeloma (RRMM).
The study achieved a statistically significant improvement in minimal residual disease (MRD) negativity rates compared to the control arm. The trial will continue to evaluate other endpoints including progression-free survival and overall survival. The safety profile remained consistent with previous studies.
Iberdomide represents the first of a new class of medicines called CELMoDs, potentially establishing a new foundation for multiple myeloma treatment. The company plans to discuss these results with health authorities.
Bristol Myers Squibb (NYSE: BMY) has scheduled its third quarter 2025 financial results announcement for October 30, 2025. The company will host a conference call with the investment community at 8:00 a.m. ET to discuss the results.
Investors and the public can access the live webcast at investor.bms.com, where related materials will be available before the call. A replay will be accessible approximately three hours after the conference concludes on the same platform.